Memphasys Limited (ASX:MEM)
Australia · Delayed Price · Currency is AUD 0.0060
-0.0010 (-14.29%)
Feb 11, 2026, 10:00 AM AEST
Memphasys Company Description
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia.
The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes.
It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals.
In addition, the company develops ambient temperature storage product for human sperm; and a medium for human sperm isolation, fertilisation and cryopreservation.
Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
Memphasys Limited
| Country | Australia |
| Founded | 2006 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 24 |
| CEO | David Ali |
Contact Details
Address: 34-36 Richmond Road Homebush, NSW 2140 Australia | |
| Phone | 61 2 8415 7300 |
| Website | memphasys.com |
Stock Details
| Ticker Symbol | MEM |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000MEM5 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Pablo Neyertz | Director of Finance |
| Prof. R. John Aitken Ph.D., ScD FRSE | Scientific Director |
| Stefan Ross | Company Secretary |